title: Use of covered Cheatham-Platinum stent as the primary modality in the treatment for native coarctation of the aorta.
abstract: BACKGROUND
  Bare stent implantation in the treatment for native and recurrent coarctation of the aorta (CoA) has become established as an alternative to surgery and balloon angioplasty. However, this modality still encounters significant complications during the procedure and/or follow-up. The covered Cheatham-Platinum (CP) stent commonly used to be chosen as a rescue treatment in these patients. The purpose of this study was to evaluate the use of covered CP stent as the primary modality in the treatment for native CoA.
  
  
  METHODS
  Twenty-five covered CP stents and 2 bare CP stents were implanted in 25 patients with native CoA. All patients after the intervention were invited for follow-up examinations.
  
  
  RESULTS
  The peak systolic gradient across the lesion decreased significantly from a median value of 67.5 mmHg (quartile range, 19.3 mmHg) to 2 mmHg (quartile range, 4.0 mmHg) (P < 0.0001). Stenotic segment diameter increased from a median value of 5.0 mm (quartile range, 1.5 mm) to 17.9 mm (quartile range, 2.5 mm) (P < 0.0001). The median ratio of diameter of the coarctation postprocedure to preprocedure was 4.2 (quartile range, 1.6). All of the CP stents were placed in the suitable position without any acute complications. During a follow-up period of up to 72 months, no complications were encountered. Most of the patients (21/25) were normotensive, apart from four patients requiring antihypertensive medication during the follow-up.
  
  
  CONCLUSIONS
  The implantation of covered CP stent as the primary modality is safe and effective in the treatment for native CoA in adolescents and adults.
authors.affiliation: Department of Radiology, Cardiovascular Institute and Fu Wai Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, China.
authors.forename: Zong-ping
authors.initials: ZP
authors.lastname: Chang
authors.forename: Shi-liang
authors.initials: SL
authors.lastname: Jiang
authors.forename: Zhong-ying
authors.initials: ZY
authors.lastname: Xu
authors.forename: Ge-jun
authors.initials: GJ
authors.lastname: Zhang
authors.forename: Lian-jun
authors.initials: LJ
authors.lastname: Huang
authors.forename: Shi-hua
authors.initials: SH
authors.lastname: Zhao
authors.forename: Jian
authors.initials: J
authors.lastname: Ling
authors.forename: Hong
authors.initials: H
authors.lastname: Zheng
authors.forename: Jing-lin
authors.initials: JL
authors.lastname: Jin
authors.forename: Wen-hui
authors.initials: WH
authors.lastname: Wu
authors.forename: Hai-bo
authors.initials: HB
authors.lastname: Hu
authors.forename: Shi-guo
authors.initials: SG
authors.lastname: Li
authors.forename: Ji-hong
authors.initials: JH
authors.lastname: Yu
authors.forename: Chao-wu
authors.initials: CW
authors.lastname: Yan
mesh_terms: D000293:Adolescent; D000328:Adult; D000800:Angioplasty, Balloon; D001017:Aortic Coarctation / Q000473:pathology / Q000503:physiopathology / Q000628:therapy*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D010984:Platinum; D015607:Stents / Q000009:adverse effects; D013599:Systole
chemical_list: D010984:Platinum